NID1
Nidogen-1
Also known as: entactin, NID, NID1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P14543
- Gene
- NID1
- Ensembl
- ENSG00000116962
- Chromosome
- 1
- Canonical length
- 1247 aa
- Protein class
- Plasma proteins, Predicted secreted proteins
- Subcellular location
- Vesicles,Mitotic spindle
- Secretome location
- Secreted to extracellular matrix
OverviewNCBI Gene
This gene encodes a member of the nidogen family of basement membrane glycoproteins. The protein interacts with several other components of basement membranes, and may play a role in cell interactions with the extracellular matrix. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1247 residues, UniProt reviewed canonical sequence.
>P14543|NID1
1 MLASSSRIRA AWTRALLLPL LLAGPVGCLS RQELFPFGPG QGDLELEDGD DFVSPALELS
61 GALRFYDRSD IDAVYVTTNG IIATSEPPAK ESHPGLFPPT FGAVAPFLAD LDTTDGLGKV
121 YYREDLSPSI TQRAAECVHR GFPEISFQPS SAVVVTWESV APYQGPSRDP DQKGKRNTFQ
181 AVLASSDSSS YAIFLYPEDG LQFHTTFSKK ENNQVPAVVA FSQGSVGFLW KSNGAYNIFA
241 NDRESVENLA KSSNSGQQGV WVFEIGSPAT TNGVVPADVI LGTEDGAEYD DEDEDYDLAT
301 TRLGLEDVGT TPFSYKALRR GGADTYSVPS VLSPRRAATE RPLGPPTERT RSFQLAVETF
361 HQQHPQVIDV DEVEETGVVF SYNTDSRQTC ANNRHQCSVH AECRDYATGF CCSCVAGYTG
421 NGRQCVAEGS PQRVNGKVKG RIFVGSSQVP IVFENTDLHS YVVMNHGRSY TAISTIPETV
481 GYSLLPLAPV GGIIGWMFAV EQDGFKNGFS ITGGEFTRQA EVTFVGHPGN LVIKQRFSGI
541 DEHGHLTIDT ELEGRVPQIP FGSSVHIEPY TELYHYSTSV ITSSSTREYT VTEPERDGAS
601 PSRIYTYQWR QTITFQECVH DDSRPALPST QQLSVDSVFV LYNQEEKILR YALSNSIGPV
661 REGSPDALQN PCYIGTHGCD TNAACRPGPR TQFTCECSIG FRGDGRTCYD IDECSEQPSV
721 CGSHTICNNH PGTFRCECVE GYQFSDEGTC VAVVDQRPIN YCETGLHNCD IPQRAQCIYT
781 GGSSYTCSCL PGFSGDGQAC QDVDECQPSR CHPDAFCYNT PGSFTCQCKP GYQGDGFRCV
841 PGEVEKTRCQ HEREHILGAA GATDPQRPIP PGLFVPECDA HGHYAPTQCH GSTGYCWCVD
901 RDGREVEGTR TRPGMTPPCL STVAPPIHQG PAVPTAVIPL PPGTHLLFAQ TGKIERLPLE
961 GNTMRKTEAK AFLHVPAKVI IGLAFDCVDK MVYWTDITEP SIGRASLHGG EPTTIIRQDL
1021 GSPEGIAVDH LGRNIFWTDS NLDRIEVAKL DGTQRRVLFE TDLVNPRGIV TDSVRGNLYW
1081 TDWNRDNPKI ETSYMDGTNR RILVQDDLGL PNGLTFDAFS SQLCWVDAGT NRAECLNPSQ
1141 PSRRKALEGL QYPFAVTSYG KNLYFTDWKM NSVVALDLAI SKETDAFQPH KQTRLYGITT
1201 ALSQCPQGHN YCSVNNGGCT HLCLATPGSR TCRCPDNTLG VDCIEQKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NID1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.32
- Highest tissue expression
- 217 nTPM
Expression across tissuesHPA
Tissue
- placenta: 217 nTPM
- adipose tissue: 106 nTPM
- colon: 90 nTPM
- breast: 85 nTPM
- endometrium: 81 nTPM
- cervix: 75 nTPM
Single-cell type
- fibroblasts: 542 nCPM
- endometrial stromal cells: 478 nCPM
- pericytes: 407 nCPM
- hepatic stellate cells: 336 nCPM
- cardiomyocytes: 295 nCPM
- decidual stromal cells: 279 nCPM
Immune cell
- intermediate monocyte: 11 nTPM
- non-classical monocyte: 7.3 nTPM
- classical monocyte: 5.7 nTPM
- myeloid DC: 4.4 nTPM
- total PBMC: 2.1 nTPM
- neutrophil: 0.4 nTPM
Brain region
- choroid plexus: 17 nTPM
- cerebral cortex: 15 nTPM
- basal ganglia: 13 nTPM
- hypothalamus: 10 nTPM
- thalamus: 9.4 nTPM
- medulla oblongata: 8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NID1.
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 316 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Focal epilepsy
- Hemiparesis
- Hydrocephalus
Disease | AutoantibodyPubMed
Conditions in which antibodies against NID1 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for NID1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Studies on the formation of glomerular immune deposits in brown Norway rats injected with mercuric chloride.
1987 · Clin Immunol Immunopathol · RCR 2.5 · 67 citations - Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome.
1995 · J Intern Med · RCR 1.7 · 49 citations - Circulating autoantibodies in patients with extracapillary glomerulonephritis.
1991 · Nephrol Dial Transplant · RCR 1.2 · 35 citations - Entactin: a possible auto-antigen in the pathogenesis of non-Goodpasture anti-GBM nephritis.
1990 · Kidney Int · RCR 0.8 · 29 citations - Circulating anti-entactin antibodies in patients with glomerulonephritis.
1991 · Kidney Int · RCR 0.4 · 11 citations
Show 1 more
- Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.
1994 · Ann Rheum Dis · RCR 0.2 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.65
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.48
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- basement membrane organization
- cell-matrix adhesion
- glomerular basement membrane development
- positive regulation of cell adhesion
- positive regulation of cell-substrate adhesion
- positive regulation of integrin-mediated signaling pathway
- positive regulation of muscle cell differentiation
- regulation of basement membrane organization
Molecular functions
- calcium ion binding
- collagen binding
- extracellular matrix structural constituent
- laminin binding
- laminin-1 binding
- proteoglycan binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- LDLR class B repeat
- EGF-type aspartate/asparagine hydroxylation site
- Thyroglobulin type-1
- EGF-like domain
- EGF-like calcium-binding domain
- NIDO domain
- G2 nidogen/fibulin G2F
- Green fluorescent protein
- Growth factor receptor cysteine-rich domain superfamily
- Six-bladed beta-propeller, TolB-like
- EGF-like calcium-binding, conserved site
- NELL2-like, EGF domain
- Complement Clr-like EGF domain
- Thyroglobulin type-1 superfamily
- NOTCH1, EGF-like calcium-binding domain
- Low-density lipoprotein receptor repeat class B
- Thyroglobulin type-1 repeat
- Nidogen-like
- G2F domain
- Calcium-binding EGF domain
- Complement Clr-like EGF-like
- EGF domain
- Coagulation Factor Xa inhibitory site
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NID1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NID1 as an antibody target. Whether an autoantibody or antibody against NID1 could matter depends on whether native NID1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NID1 is annotated as secreted, so native NID1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label NID1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...